INSTINCT BIO TECHNICAL CO HOLDINGS INC. (BIOT) Form 6-K — Oct 1, 2026
BIOT announced that CelSiege Biosciences has named it non-exclusive authorized introduction and business development representative in Japan and China for IN01, a clinical-stage cancer immunotherapy targeting EGF. Under a Letter of Authorisation signed September 18, 2026, BIOT may introduce the program to potential partners and facilitate discussions on licensing, co-development, and commercialization. IN01 is a therapeutic cancer vaccine with squamous non-small cell lung cancer as the lead indication; it has not received marketing approval and any definitive transaction remains subject to separate negotiations and due diligence.
Key figures
- Lung cancer deaths 2022
- approximately 1.8 million
- Lung cancer new cases 2022
- approximately 2.5 million
- Nsclc share of lung cancer
- 80% to 85%
- Nsclc market estimate 2025 usd
- $38.49 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.